Daily Finance -- Major pharmaceutical companies aren't usually quick to form partnerships with small biotechs, unless the big guys see a promise of getting their hands on attractive new drug candidates. Well, little-known biopharmaceutical outfit Micromet (MITI) has attracted not just one but seven Big Pharmas that have signed partnership pacts to help develop some of its products. Micromet's No. 1 appeal: It's developing novel antibody-based drugs to treat cancer, inflammatory and autoimmune diseases.
